$JOUT

Johnson Outdoors director Stevens sells $299,125 in stock

Johnson Outdoors director Edward A. Stevens sold 6,250 shares for $299,125 at $47.86 each. He now holds 10,640 shares. The stock is up 23.6% year-over-year. Q3 earnings beat estimates with $1.42 EPS vs. $0.93 expected, but revenue missed at $189.73M vs. $193.21M. The company has paid dividends for 14 years, yielding 2.76%.

Original reporting
Published Aug 19, 2026, 3:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 19, 2026, 6:35 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$JOUT
Neutral
high confidence
Mentioned
$JOUT
Relevance
4/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$JOUTNeutralLow
01

Why it matters

The insider sale adds a minor data point to recent positive earnings momentum.

02

Market read

Small insider transaction amid recent earnings beat; limited trading relevance.

03

What to watch

Potential upcoming strategic changes not disclosed; monitor future filings.

Relevance 4/10Novelty 3/10Timing: post‑market on Aug 19, 2026

Background

Johnson Outdoors reported Q3 earnings beat EPS but missed revenue expectations; stock up 23.6% YTD.

Company-level read

Ticker impact

$JOUTNeutralHigh confidence
Context

Director Edward A. Stevens sold 6,250 JOUT shares for $299,125 on Aug 18, 2026.

Expected impact

minimal impact; price likely unchanged

Evidence & confidence

Sale size is modest relative to float and recent price surge; no broader implications.

Market effects

None; insider activity does not affect outdoor recreation sector broadly.

None; impact confined to Johnson Outdoors shareholders.

Low; limited to US-listed small‑cap investors.

Counterpoint

Insider sell could be a red flag if followed by further disposals.

Key entities

  • Johnson Outdoors Inc.

    Outdoor recreation equipment manufacturer (NASDAQ:JOUT).

  • Edward A. Stevens

    Director of Johnson Outdoors.

Related articles

$JOUTMedAI 8/10

Johnson Outdoors (JOUT) Q3 2026 Earnings Call Transcript

Johnson Outdoors (NASDAQ:JOUT) reported Q3 FY2026 net sales of $189.7 million, up 5% y/y, driven by fishing and diving. Fishing revenue rose 7% to $150.0 million, diving rose 10% to $23.3 million, while camping and watercraft fell 13% to $16.4 million. Gross margin was 45.3% aided by $15 million tariff refunds; diluted EPS was $1.42. Debt was $0.

$JOUTMedAI 8/10

Johnson Outdoors (JOUT) Q3 2026 Earnings Call Transcript

Johnson Outdoors (JOUT) reported Q3 FY2026 net sales of $189.7 million, up 5% YoY, led by fishing and diving. Fishing revenue rose to $150.0 million (+7%) and diving to $23.3 million (+10%). Gross margin was 45.3% aided by $15 million tariff refunds; operating income was $18.3 million. Net income was $14.9 million, diluted EPS $1.42. Cash was $175.2 million; debt was $0.

$JOUTMed

Johnson Outdoors Q3 Earnings Call Highlights

Johnson Outdoors (NASDAQ:JOUT) reported Q3 results discussed on its earnings call. Management cited weaker market conditions but said Jetboil remains a leader and Old Town watercraft demand is resilient. CFO Asad Rahman said Q3 gross margin rose to 45.3% aided by about $15M tariff refunds; profit before tax was $23.3M vs $10.5M a year earlier. Full-year tax expense expected at $5M to $6M.

$JOUTMed

JOHNSON OUTDOORS INC (JOUT): Results of Operations and Financial Condition

JOHNSON OUTDOORS INC (JOUT) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Johnson Outdoors Reports Fiscal Third Quarter Results RACINE, Wis., Aug. 07, 2026 (GLOBE NEWSWIRE) -- Johnson Outdoors Inc. (Nasdaq:JOUT) , a leading global innovator of outdoor recreation equipment and technology, today announced operating results for the Company’s

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.